Abcodia is a clinical stage company engaged in the development of novel tests for the early detection of cancer. The Company’s first product is the ROCA® Test for the early detection of ovarian cancer.
Abcodia’s products are based on expertise in measuring and modelling dynamic changes over time of clinical variables including test results from serum-based markers before cancer is clinically diagnosed. The company maintains exclusive commercial access to a biobank of prospectively collected samples donated from over 200,000 individuals over a 10-year period for the purpose of studies in the early detection and screening of cancer.
Abcodia is a privately held company funded through investments from Albion Ventures, Cambridge Innovation Capital, Scottish Equity Partners and UCL Business. The company is headquartered in U.K.